BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 2159104)

  • 1. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
    Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
    Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Sato H; Sato Y
    Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Humoral response to the injection of acellular Pertussis vaccine].
    Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.
    Sato H; Sato Y
    Infect Immun; 1984 Nov; 46(2):415-21. PubMed ID: 6542069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
    Sato H; Sato Y
    Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.
    Kimura A; Mountzouros KT; Relman DA; Falkow S; Cowell JL
    Infect Immun; 1990 Jan; 58(1):7-16. PubMed ID: 2294058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
    Watanabe M; Nagai M
    Infect Immun; 2001 Nov; 69(11):6981-6. PubMed ID: 11598073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species.
    Munoz JJ; Peacock MG
    Microbiol Immunol; 1989; 33(4):341-55. PubMed ID: 2549344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
    Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
    Thomas MG; Ashworth LA; Miller E; Lambert HP
    J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.
    Wong KH; Skelton SK
    J Clin Microbiol; 1989 Dec; 27(12):2805-10. PubMed ID: 2556434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to pertussis toxin and filamentous haemagglutinin in NIH mice immunized with the International Standard for Pertussis Vaccine.
    Manghi MA; Dellepiane NI; Eriksson PV; Di Paola G; De Dios FH
    Biologicals; 1990 Jul; 18(3):165-72. PubMed ID: 2257129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes.
    Wiertz EJ; Walvoort HC; Van Loveren H; Van Straaten-Van De Kappelle I; Van Der Gun JW; Kreeftenberg JG
    Biologicals; 1990 Jul; 18(3):173-80. PubMed ID: 2257130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
    Sato Y; Sato H
    Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
    Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
    Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertussis whole cell vaccine: relation between intracerebral protection in mice and antibody response to pertussis toxin, filamentous hemagglutinin and adenylate cyclase.
    Dellepiane NI; Manghi MA; Eriksson PV; di Paola G; Cangelosi A
    Zentralbl Bakteriol; 1992 Jun; 277(1):65-73. PubMed ID: 1520970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.